Patient-derived xenograft tumors retain histological characteristics that are similar to the patient tumors from which they were derived. Thus, these models are thought to be closer to the clinical situation than traditional xenograft models. The Patient-Derived Xenograft (PDX) Core provides a valuable model of human cancer that enables investigators to extend their observations to actual patient tumor cells.
The Core creates and maintains carefully delineated, in vivo human tumor models from a broad range of histologies that retain the characteristics of fresh human tumors. These PDX models are passaged continuously in vivo and are never exposed to tissue culture plastic and the limitations imposed by tissue culture selection of certain tumor cell clones.
The Core builds on an already established PDX repository infrastructure that currently maintains sixty-two models covering ten different tumor histologies, with 2-3 new models created each week. Early passage cell lines are created in parallel from these in vivo PDX models and are available to the Physical Sciences Oncology Network investigators.
These early passage cell lines will be utilized for in vitro experiments by all three CR-PSOC research projects. The phenotypic and genotypic uniformity of these cells enables the integration of data across all three projects. In addition, the Core creates new PDX models of human multiple myeloma and medulloblastoma since potassium imbalances have been implicated in the tumorigenicity and progression of these tumor types.